Literature DB >> 22906767

IFNs, ISGylation and cancer: Cui prodest?

Andrea Sgorbissa1, Claudio Brancolini.   

Abstract

IFNs are cytokines that segregate viral infections, modulate the immune responses and influence tumor cells survival. These options are under the control of ISGs (Interferon Stimulated Genes) which expression is propelled by IFNs. To the ISGs family belong all the components of the molecular machinery that modifies proteins by the addition of the ubiquitin-like protein ISG15, in a process known as ISGylation. Despite alterations in the components of this machinery are frequently observed in cancer, the contribution of ISG15 and of ISGylation to tumor growth and resistance to chemotherapy is unclear and debated. With the aim of elucidating this point, in this review we have discussed about recent data pointing to a dysregulation of the IFN signaling and the ISGylation system in cancer.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22906767     DOI: 10.1016/j.cytogfr.2012.07.003

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  14 in total

1.  The DeISGylase USP18 limits TRAIL-induced apoptosis through the regulation of TRAIL levels: Cellular levels of TRAIL influences responsiveness to TRAIL-induced apoptosis.

Authors:  Ivana Manini; Andrea Sgorbissa; Harish Potu; Andrea Tomasella; Claudio Brancolini
Journal:  Cancer Biol Ther       Date:  2013-09-19       Impact factor: 4.742

2.  Promyelocytic Leukemia Protein (PML) Requirement for Interferon-induced Global Cellular SUMOylation.

Authors:  Mohamed Ali Maroui; Ghizlane Maarifi; Francis P McManus; Frédéric Lamoliatte; Pierre Thibault; Mounira K Chelbi-Alix
Journal:  Mol Cell Proteomics       Date:  2018-03-13       Impact factor: 5.911

3.  Dual regulation of Stat1 and Stat3 by the tumor suppressor protein PML contributes to interferon α-mediated inhibition of angiogenesis.

Authors:  Kuo-Sheng Hsu; Xuan Zhao; Xiwen Cheng; Dongyin Guan; Ganapati H Mahabeleshwar; Yu Liu; Ernest Borden; Mukesh K Jain; Hung-Ying Kao
Journal:  J Biol Chem       Date:  2017-04-21       Impact factor: 5.157

Review 4.  Interferon-stimulated genes: a complex web of host defenses.

Authors:  William M Schneider; Meike Dittmann Chevillotte; Charles M Rice
Journal:  Annu Rev Immunol       Date:  2014-02-06       Impact factor: 28.527

5.  ISG15 as a novel prognostic biomarker for hepatitis B virus-related hepatocellular carcinoma.

Authors:  Xiaoxin Qiu; Yuan Hong; Darong Yang; Man Xia; Haizhen Zhu; Qinglong Li; Hailong Xie; Qunfeng Wu; Chen Liu; Chaohui Zuo
Journal:  Int J Clin Exp Med       Date:  2015-10-15

6.  STAT3-activated GM-CSFRα translocates to the nucleus and protects CLL cells from apoptosis.

Authors:  Ping Li; David Harris; Zhiming Liu; Uri Rozovski; Alessandra Ferrajoli; Yongtao Wang; Carlos Bueso-Ramos; Inbal Hazan-Halevy; Srdana Grgurevic; William Wierda; Jan Burger; Susan O'Brien; Stefan Faderl; Michael Keating; Zeev Estrov
Journal:  Mol Cancer Res       Date:  2014-05-16       Impact factor: 5.852

7.  Free ISG15 triggers an antitumor immune response against breast cancer: a new perspective.

Authors:  Julian Burks; Ryan E Reed; Shyamal D Desai
Journal:  Oncotarget       Date:  2015-03-30

8.  Structural basis of the specificity of USP18 toward ISG15.

Authors:  Paul P Geurink; Annika Röcker; Anja Basters; Katharina F Witting; Roya Tadayon; Sandra Hess; Marta S Semrau; Paola Storici; Huib Ovaa; Klaus-Peter Knobeloch; Günter Fritz
Journal:  Nat Struct Mol Biol       Date:  2017-02-06       Impact factor: 15.369

9.  LIPG signaling promotes tumor initiation and metastasis of human basal-like triple-negative breast cancer.

Authors:  Pang-Kuo Lo; Yuan Yao; Ji Shin Lee; Yongshu Zhang; Weiliang Huang; Maureen A Kane; Qun Zhou
Journal:  Elife       Date:  2018-01-19       Impact factor: 8.140

10.  UBE2L6/UBCH8 and ISG15 attenuate autophagy in esophageal cancer cells.

Authors:  Chloe M Falvey; Tracey R O'Donovan; Shereen El-Mashed; Michelle J Nyhan; Seamus O'Reilly; Sharon L McKenna
Journal:  Oncotarget       Date:  2017-04-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.